AI Development

FDA and EMA issue AI principles for drug development

January 15, 2026 · High importance · policy
Editorial Analysis

The joint principles establish guidance for AI use across drug lifecycle from research to manufacturing. This standardizes practices to accelerate innovation and reduce animal testing while ensuring patient safety in pharmaceutical AI applications.

At a Glance
Date
January 15, 2026
Importance
High 4/5
Category
policy
Axis of Change
Regulatory Constraint
Organizations
FDA EMA
Models Affected
No specific model identified
Sources
  1. 01 pharma.economictimes.indiatimes.com
Related Developments
Sep 17, 2026 · policy

US open to discussing shared AI risks with China, Bessent says
Sep 17, 2026 · policy

Court filings show OpenAI and Microsoft executives described AI as news substitute
Sep 16, 2026 · policy

AI lab leaders call for slowdown citing recursive self-improvement risks